Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
Conclusion.Our modeling analysis suggests that nFOLFIRINOX is preferable to upfront surgery for patients with BR/LA PDAC from both an effectiveness and cost‐effectiveness standpoint. Additional clinical data that further define the long‐term effectiveness of nFOLFIRINOX are needed to confirm our results.Implications for Practice.Increasingly, neoadjuvant FOLFIRINOX has been used for borderline resectable and locally advanced pancreatic cancer with the goal of rendering them resectable and decreasing risk of recurrence. Despite many efforts to show the benefits of neoadjuvant over adjuvant therapies, clinical evidence to guide this decision is largely lacking. Decision‐analytic modeling can provide a methodologic platform that integrates the best available data to quantitatively explore clinical decisions by simulating a hypothetical clinical trial. This modeling analysis suggests that neoadjuvant FOLFIRINOX is preferable to upfront surgery and adjuvant therapies by various outcome metrics including quality‐adjusted life years, overall survival, and incremental cost‐effectiveness ratio.
Source: The Oncologist - Category: Cancer & Oncology Authors: Jin G. Choi, Ryan D. Nipp, Angela Tramontano, Ayman Ali, Tiannan Zhan, Pari Pandharipande, Emily C. Dowling, Cristina R. Ferrone, Theodore S. Hong, Deborah Schrag, Carlos Fernandez-Del Castillo, David P. Ryan, Chung Yin Kong, Chin Hur Tags: Health Outcomes and Economics of Cancer Care, Gastrointestinal Cancer Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Clinical Trials | Economics | Gastroenterology | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Xeloda